International practice patterns and resource utilization in the treatment of neuroendocrine tumors

Pancreas

Volumn 42, Issue 2, 2013, Pages 339-347

  Casciano, Roman ^a   Wang, Xufang ^b   Stern, Lee ^a   Parikh, Rohan ^a   Chulikavit, Maruit ^a   Willet, Jacob ^a   Liu, Zhimei ^b   Strosberg, Jonathan ^c   Cadiot, Guillaume ^d   Riechelmann, Rachel ^e  

^a LA SER Analytica   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d SERVICE DE DERMATOLOGIE   (France)

^e Clinical Research   (Brazil)

Author keywords

NET; neuroendocrine tumor; practice patterns; resource utilization

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; IMATINIB; IRINOTECAN; MITOTANE; OXALIPLATIN; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; VINCRISTINE;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURGERY; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; GASTROINTESTINAL TUMOR; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; LUNG TUMOR; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PHYSICIAN; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAZIL; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; EUROPE; HEALTH CARE SURVEYS; HEALTH RESOURCES; HEALTHCARE DISPARITIES; HUMANS; INTERNATIONALITY; LINEAR MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROENDOCRINE TUMORS; ODDS RATIO; PHYSICIAN'S PRACTICE PATTERNS; RESIDENCE CHARACTERISTICS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84874108689     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31826707cc     Document Type: Article

References (26)

1. Modlin IM, Moss SF, Oberg K, et al. Gastrointestinal neuroendocrine (carcinoid) tumours: Current diagnosis and management. Med J Aust. 2010;193(1):46-52.
2. Yao JC, Hassan M, Phan A, et al. One hundred years after ''carcinoid'': Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18): 3063-3072.
3. Ong SL, Garcea G, Pollard CA, et al. A fuller understanding of pancreatic neuroendocrine tumours combined with aggressive management improves outcome. Pancreatology. 2009;9(5):583-600.
4. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25(3):458-511.
5. Vinik E, Carlton CA, Silva MP, et al. Development of the Norfolk quality of life tool for assessing patients with neuroendocrine tumors. Pancreas. 2009;38(3):e87-e95.
6. Davies AH, Larsson G, Ardill J, et al. Development of a disease-specific Quality of Life questionnaire module for patients with gastrointestinal neuroendocrine tumours. Eur J Cancer. 2006;42(4):477-484.
7. Kulke M, Clark O, Benson A, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Neuroendocrine Tumors Version 1.2011. Fort Washington, PA: National Comprehensive Cancer Network; 2011.
8. Salazar R, Wiedenmann B, Rindi G, et al. ENETS 2011 Consensus Guidelines for the management of patients with digestive neuroendocrine tumors: An update. Neuroendocrinology. 2012;95(2):71-73.
9. Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157-176.
10. Pape UF, Perren A, Niederle B, et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology. 2012;95(2):135-156.
11. Jensen RT, Cadiot G, Brandi ML, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95(2):98-119.
12. Falconi M, Bartsch DK, Eriksson B, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012;95(2):120-134.
13. Delle Fave G, Kwekkeboom DJ, Van Cutsem E, et al. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology. 2012;95(2):74-87.
14. Abu HM, McPhail MJ, Zeidan BA, et al. Aggressive multi-visceral pancreatic resections for locally advanced neuroendocrine tumours. Is it worth it? JOP. 2009;10(3):276-279.
15. Dimitroulopoulos D, Xynopoulos D, Tsamakidis K, et al. Scintigraphic detection of carcinoid tumors with a cost effectiveness analysis. World J Gastroenterol. 2004;10(24):3628-3633.
16. Norton JA, Fraker DL, Alexander HR, et al. Surgery increases survival in patients with gastrinoma. Ann Surg. 2006;244(3):410-419.
17. Delea TE Jr. Association between time to disease progression endpoints and overall survival in patients with neuroendocrine tumors. Poster presented at the 8th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. 2011.
18. Lebwohl D, Kay A, Berg W, et al. Progression-free survival: Gaining on overall survival as a gold standard and accelerating drug development. Cancer J. 2009;15(5):386-394.
19. Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: Consensus report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. J Clin Oncol. 2011;29(7):934-943.
20. Riechelmann RP, Rego J. Progression-free survival in neuroendocrine tumors: Preferred end point, but how should it be defined? J Clin Oncol. 2011;29(20):2835-2836.
21. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514-523.
22. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501-513.
23. Bodei L, Ferone D, Grana CM, et al. Introduction: Neuroendocrine Tumors. 2009 Available at: http://dissertations.ub.rug.nl/FILES/faculties/medicine/2009/ l.bodei/01c1.pdf. Accessed April 12, 2012.
24. Hanley JA, Negassa A, Edwardes MD, et al. Statistical analysis of correlated data using generalized estimating equations: An orientation. Am J Epidemiol. 2003;157(4):364-375.
25. Boudreaux JP, Klimstra DS, Hassan MM, et al. appendix, and cecum. Pancreas. 2010;39(6):753-766.
26. Cadiot G. Thesaurus national de cancerologie digestive: Chapitre 11 tumeurs endocrines digestives. Paris, France: Socie'té Nationale Française de Gastroente'rologie; 2011.